Home › Compound Library › CJC-1295 DAC

CJC-1295 DAC

Peptidesubcutaneous · inferred

CJC-1295 with Drug Affinity Complex (DAC) - a maleimidopropionic acid linker that covalently bonds to serum albumin after injection. This extends the half-life to ~6-8 days (vs 30 min without DAC), producing continuous GH elevation rather than pulsatile release. Dosed 1-2 mg SC once or twice weekly. Creates a sustained, non-physiological GH elevation pattern.

Projected serum levels — 1k mcg (≈ 1 mg), weekly

CJC-1295 DAC
CJC-1295 DAC modeled serum levels, 1k mcg (≈ 1 mg) weekly over 56 days Population-based pharmacokinetic estimate. Steady state reached after approximately 21 days. 0 0.25 0.50 0.75 1 Day 0 Day 14 Day 28 Day 42 Day 56 Time on a regular schedule ≈ steady state · day 21
CJC-1295 DAC modeled serum levels with a loading dose of 2.2k mcg, then 1k mcg (≈ 1 mg) weekly The first dose is larger so levels approach steady state faster. 0 0.25 0.50 0.75 1 Day 0 Day 14 Day 28 Day 42 Day 56 Time on a regular schedule

Maintenance schedule: 1k mcg (≈ 1 mg) weekly (subcutaneous).

Loading schedule: 2.2k mcg on day 1, then 1k mcg (≈ 1 mg) weekly — reaching therapeutic levels sooner.

Modeled steady state after ~21 days: peak ≈ 0.96 mg, trough ≈ 0.70 mg body load. Population-based estimate over 56 days for a reference dose at a 70 kg reference body mass — the interactive app scales curves to your doses, timing, and body mass.

Key facts

Category
Peptide
Route modeled
Subcutaneous
Model confidence
inferred
Half-life
7 days
Common dose
1k mcg (≈ 1 mg)
Suggested maximum
2k mcg/day
Reference dose range
500–2k mcg (single dose)
Suggested cadence
weekly

Documented interactions

  • watch
    CJC-1295 (no DAC) / Mod GRF 1-29 + CJC-1295 DAC Stacked effects

    CJC-1295 DAC and CJC-1295 (no DAC) / Mod GRF 1-29 both push the ghrh receptor in the same direction.

  • watch
    Tesamorelin (Egrifta) + CJC-1295 DAC Stacked effects

    CJC-1295 DAC and Tesamorelin (Egrifta) both push the ghrh receptor in the same direction.

Serum checks 2 modeled interaction pairings for cjc-1295 dac across your whole stack — absorption conflicts, enzyme inhibition, and nutrient depletion included.

Research behind this entry

  1. Prolonged stimulation of growth hormone and insulin-like growth factor I secretion by CJC-1295, a long-acting analog of GH-releasing hormone, in healthy adults Teichman SL, Neale A, Lawrence B, Gagnon C, Castaigne JP, Frohman LA · Journal of Clinical Endocrinology & Metabolism, 2006 DOI

    Clinical study establishing CJC-1295 DAC half-life of 5.8-8.1 days with sustained GH elevation for 6+ days and IGF-I elevation for 9-11 days after single injection, demonstrating the dramatic effect of albumin…

1 published study referenced in the app, each with a plain-language summary.